. 2014 Oct;58(10):6068–6078. doi: 10.1128/AAC.02538-14

TABLE 3.

Clearance of antimalarial drugs in malaria-infected patients compared to healthy adults

Drug	Route of administration^a	CL (liters/h/kg) (no.of groups^b)		Healthy vs. malaria		References^b
Drug	Route of administration^a	Healthy	Malaria	P value	Power	References^b
Artesunate	IV	1.9 ± 0.6 (3)	2.9 ± 0.8 (8)	0.09	0.4	55, 60, 62, 125 –130
Dihydroartemisinin (from IV artesunate)	IV	1.11 ± 0.16 (3)	0.81 ± 0.2 (8)	0.04	0.56	55, 60, 62, 125 –131
Artemether	IM	0.88 ± 0.35 (2)	1.8 ± 0.9 (2)	0.32	0.13	64, 65, 132, 133
Piperaquine^c	Oral	0.86 ± 0.65 (6)	1.55 ± 0.73 (4)	0.15	0.28	56, 88, 90, 91, 134 –137, 154
Mefloquine	Oral	0.030 ± 0.014 (17)	0.039 ± 0.014 (5)	0.24	0.21	94 –109, 138, 139
Quinine	IV	0.17 ± 0.05 (6)	0.07 ± 0.03 (9)	0.0002	0.99	112, 114 –117, 122, 140 –145
Quinine (children)	IV	0.24 (1)	0.064 ± 0.014 (5)	NA^d	NA	118, 146, 147

IV, intravenous; IM, intramuscular.

Data are means ± SD. Some studies comprised several groups.

Piperaquine studies included piperaquine alone and piperaquine-dihydroartemisinin data for healthy volunteers, but only piperaquine-dihydroartemisinin data for patients with malaria. Our data and a previous report (148) indicate that there is no significant difference in piperaquine clearance when administered alone or in combination with dihydroartemisinin.

NA, not applicable.